MedTrace Logo

French Aquablation Clinical Investigation Using Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue

NCT03191734 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2019-02-22

No results posted yet for this study

Summary

Single arm, multi-center prospective clinical trial to determine the safety and effectiveness of the AQUABEAM System in the treatment of benign prostatic hyperplasia (BPH) in men 45 to 80 years of age.

Conditions

  • Benign Prostatic Hyperplasia (BPH)

Interventions

DEVICE

AQUABEAM System

Aquablation is a minimally invasive transurethral surgical procedure using the AQUABEAM system, a personalized image-guided waterject resection system that utilizes a high-pressure saline stream to resect and remove prostate tissue.

Sponsors & Collaborators

  • PROCEPT BioRobotics

    lead INDUSTRY

Principal Investigators

  • Aurelien Descazeaud, MD · Centre Hospitalier Régional Universitaire de Limoges

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-19
Primary Completion
2018-07-02
Completion
2019-01-07

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03191734 on ClinicalTrials.gov